Granules India’s Jeedimetla facility completed the US FDA inspection

Granules India’s Jeedimetla facility completed the US FDA inspection

Jeedimetla facility manufactures Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFIs).

FPJ Web DeskUpdated: Friday, June 23, 2023, 03:42 PM IST
article-image
Granules India’s Jeedimetla facility completed the US FDA inspection | Image: Granules (Representative)

Granules Jeedimetla facility located at Hyderabad, Telangana, India has successfully completed the US FDA’s surveillance inspection with zero observations, the company announced through an exchange filing. The inspection was completed between June 19 and June 23.

Jeedimetla facility manufactures Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFIs).

Granules shares

The shares of Granules on Friday closed at Rs 286.95, down by 0.35 per cent.

RECENT STORIES

Reliance Industries Reports ₹2.73 Lakh Crore Q1 Revenue, Jio And Retail Lead Growth; Mukesh Ambani...

Reliance Industries Reports ₹2.73 Lakh Crore Q1 Revenue, Jio And Retail Lead Growth; Mukesh Ambani...

Bandhan Bank Q1 Net Profit Plunges 65% YoY; NII Falls 7.7% Amid Challenging Environment

Bandhan Bank Q1 Net Profit Plunges 65% YoY; NII Falls 7.7% Amid Challenging Environment

Morgan Stanley Projects RBI Rate Cut In October As India’s Inflation Falls To Multi-Year Low

Morgan Stanley Projects RBI Rate Cut In October As India’s Inflation Falls To Multi-Year Low

JSW Steel Q1 Net Profit Jumps 47% To ₹2,209 Crore Despite 3.7% Drop In Revenue To ₹43,147 Crore

JSW Steel Q1 Net Profit Jumps 47% To ₹2,209 Crore Despite 3.7% Drop In Revenue To ₹43,147 Crore

Sensex Tanks 501 Points, Bank Stock Selloff & FII Outflows Drag Markets

Sensex Tanks 501 Points, Bank Stock Selloff & FII Outflows Drag Markets